Cancer 3 revealed only one additional lymphoma with the t(2;12)(p12;p13), which was also diagnosed as typical MCL. 4 Unfortunately, gene expression profiling was not available in the cases presented here. Nevertheless, the typical morphologic and immunophenotypic features of our cases indicate that rare cyclin D1-negative MCLs exist, in which deregulation of cyclin D2 due to a t(2;12)(p12;p13) substitutes for t(11;14)-driven cyclin D1 expression. Schleswig-Holstein Campus Kiel, Germany; Schwanenweg 14, 24105 Kiel, Germany; e-mail: rsiebert@medgen.uni-kiel.de. Supported from grants of the Deutsche , the Lymphoma Research Foundation (New York), and the European Union (European MCL Network, LSHC-CT-2004-503351 To the editor:
To the editor:
Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells
We read the letter by Grogg et al, 1 recently published in Blood, with great interest. The authors demonstrated that CD10 ϩ T cells in angioimmunoblastic T-cell lymphoma 2 (AITL) coexpress CXCL13 and proposed that AITL is a neoplasm of germinal center (GC) T-helper cells.
We have hypothesized that neoplastic T cells may be related to follicular B helper T (T FH ) cells, [3] [4] [5] [6] since CD10 ϩ atypical T cells were found to be in intimate contact with the expanded meshwork of proliferating follicular dendritic cells (FDCs), a characteristic of AITL. Therefore, we have performed consecutive double immunolabeling to analyze expression of some known T FH cell functional antigens (CXCR5, CD154/CD40L, CD134/OX40, and CD57) in the CD10 ϩ T cells in 20 paraffin-embedded AITL cases. Since Kim et al 7 and Chtanova et al 8 established that CXCL13 is highly up-regulated in T FH cells, expression of this antigen was also investigated; the same has also been done by Grogg et al. 1 In 18 of 20 cases, the expression of CD10 on 5% to 30% of T cells strongly correlated with CXCL13 production. The remaining 2 cases exhibited CXCL13 ϩ atypical T cells without apparent CD10 expression. The neoplastic T cells, as defined by CD10 as well as CXCL13 expression, revealed a CXCR5 ϩ CD134 ϩ CD154 ϩ CD57 Ϫ/ϩ immunophenotype (Figure 1) , which is most consistent with GC outer-zone T FH cells. 6 All cases displayed concomitant expression of CXCL13 and CXCR5 in neoplastic T cells, again pointing to a T FH phenotype. [3] [4] [5] [6] [7] [8] Coexpression of the CXCR5 chemokine receptor and its ligand CXCL13 suggests an autocrine loop, possibly contributing to the survival of neoplastic T cells. All cases demonstrated coexpression of CD154 in the majority of the neoplastic T cells. This antigen plays a crucial role in GC formation 9 and provides survival signals to follicular B cells. 6 Each case showed significant but variable numbers (10%-100%) of CXCL13 ϩ T cells bearing CD134, whose expression on activated CD4 ϩ T cells either initiates their migration into or causes them to be retained in B follicles. 10 One case coexpressed CD57 in a significant proportion of neoplastic cells, while the remaining cases displayed only a minute fraction of CD57 ϩ CXCL13 ϩ cells that may reflect the residual normal T FH cells. Since proliferating FDCs expressed CXCL13 and are known to express CD40 9 (receptor for CD154) and OX40L 6,10 (ligand for CD134), our data suggest a selective cross-talk between FDCs and neoplastic T cells.
Our observations not only fully support the notion of Grogg et al 1 but extend it by a more detailed analysis, establishing that the phenotype of the neoplastic cells (as shown here) is consistent with activated T FH cells localized at the boundary between the mantle zone and the GC light zone. 6 These findings provide direct explanations for some peculiar features of AITL, including B-cell hyperactivation and hypergammaglobulinemia despite gradual reduction of follicular B-cell mass, as well as the follicular outgrowths of FDCs as a result of stimulation by neoplastic T FH cells. Further investigations will be needed to explain loss of follicular B cells, a phenomenon that occurs in advanced cases and may be caused by a disarranged dialogue between neoplastic T FH cells and nonneoplastic B cells.
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The cases studied were obtained from the Hungarian T-Cell Lymphoma Register. To the editor:
Immune thrombocytopenic purpura does not exhibit a disparity in prevalence between African American and white veterans Ethnic, racial, and geographic differences influence virtually all human disease, and certain conditions exhibit well-established differences between Africans and Europeans. 1 Once such differences are identified, it is important to examine them, because etiologic, genetic, and therapeutic heterogeneity may be present. 2, 3 In addition, ethnic disparities of all types may be accompanied by BLOOD, 1 AUGUST 2006 ⅐ VOLUME 108, NUMBER 3
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